Epigenic Therapeutics Secures $60 Million to Enhance Therapies

Significance of Recent Financing for Epigenic Therapeutics

Epigenic Therapeutics, a pioneering company focused on innovative gene modulation therapies, has successfully completed a significant financing round. This funding, amounting to $60 million, was led by Lapam Capital and included continued support from existing investors as well as interest from new investors. This investment plays a crucial role in propelling the clinical development of promising treatments and technologies aimed at addressing chronic health conditions.

Optimizing Development of Epigenetic Medicines

The primary objective of this funding is to further the clinical development of EPI-003, a promising candidate aimed at providing a functional cure for chronic hepatitis B. Alongside this, funding will support EPI-001 for the treatment of hypercholesterolemia. These advancements showcase Epigenic’s commitment to developing effective therapies that target prevalent health challenges.

Innovative Technology Platforms at Epigenic

One of the standout features of Epigenic is its proprietary EPIREG™ technology platform. This cutting-edge platform enables specific and sustained silencing of target genes through precise mechanisms such as DNA methylation and histone modification. Unlike traditional gene-editing tools, which pose various safety risks, EPIREG™ represents a revolutionary approach to therapeutics, significantly enhancing patient safety in chronic disease treatment.

Expanding Delivery Mechanisms

In addition to EPIREG™, Epigenic has developed the EpiTax™ platform, an advanced delivery system designed to precisely deliver therapeutic agents to the liver and other organs. This innovation broadens EPIREG™'s potential applications, enriching Epigenic's overall technological framework and positioning it competitively within the biotechnology landscape.

Empowering Epigenetic Medicine Through AI

The AIAID™ platform, another novel system developed by Epigenic, streamlines the design and modulation processes of epigenetic treatments. This platform integrates a self-developed model that supports core epigenetic data analysis and decision-making. Utilizing a virtual lab concept, AIAID™ facilitates tasks essential for research advancement, including target selection, sgRNA design, and the evaluation of potential therapies.

Leadership and Vision

Dr. Bob Zhang, the CEO and Co-founder of Epigenic Therapeutics, expressed gratitude toward the investors for their trust and support. Since its establishment, the company has achieved significant milestones in advancing epigenetic technologies and remains focused on delivering safe and effective therapies to patients as quickly as possible. Notably, industry leaders recognize Epigenic's potential for fostering innovation in epigenetic therapies.

Community Support from Investors

Mr. Zhihua Yu, Chairman of Lapam Capital, acknowledged the unique advantages that Epigenic brings to the field of drug development. The technological foundation established by EPIREG™ and EpiTax™ positions the firm for future breakthroughs in clinical trials, further allowing them to solidify their presence in the innovative healthcare space.

About Epigenic Therapeutics

As a forefront biotechnology company established in 2021, Epigenic Therapeutics is committed to developing next-generation gene modulation therapies. The company focuses on leveraging epigenetic regulation to treat a variety of diseases, and develops several promising product candidates aimed at metabolic, cardiovascular, and autoimmune diseases.

About Lapam Capital

Lapam Capital is a leading venture capital firm that specializes in the biomedical sector. The firm has managed multiple funds, focusing on innovative pharmaceuticals and medical devices. Their strategy emphasizes supporting early to mid-stage companies, thus fostering growth within the biotech sector.

Frequently Asked Questions

What is the purpose of the recent financing for Epigenic Therapeutics?

The financing aims to support the clinical development of EPI-003 and EPI-001, crucial treatments targeting hepatitis B and hypercholesterolemia.

What technologies are being developed at Epigenic Therapeutics?

Epigenic is advancing technologies like EPIREG™ for gene modulation and EpiTax™ for targeted drug delivery, enhancing safety and efficacy in treatments.

Who are the key investors in Epigenic Therapeutics?

The recent funding round was led by Lapam Capital, with participation from existing investors such as Qiming Venture Partners and OrbiMed, along with new investors.

What challenges does Epigenic aim to address?

Epigenic focuses on prevalent chronic diseases, intending to develop safe and effective therapies while mitigating safety concerns associated with traditional gene editing.

How can I learn more about Epigenic Therapeutics?

For further information, individuals can explore Epigenic's website to understand their mission, technologies, and ongoing projects.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.